Skip to content

#其他

Today 0 items
Oct 15Thu
  1. statnews.com51

    How consumer tech company Whoop is building for Medicare patients

    Whoop joined Medicare's 10-year ACCESS pilot, offering its wearable, a 12-month app subscription, and clinician support at no cost to traditional Medicare patients 65 and up with high blood pressure, high cholesterol, obesity, or prediabetes. Chief medical officer Ami Bhatt, speaking at the STAT Summit in Boston, said the company must improve measures such as blood pressure, hemoglobin A1C, and LDL cholesterol to receive full payment, and is working with the National Council on Aging and AARP on personalization, with app simplification first on the roadmap.

Oct 14Wed
  1. biospace.com46

    GSK plans 1.2K+ layoffs at Belgium sites as $2.5B restructure gains momentum

    GSK will cut up to 1,217 jobs across its Rixensart, Wavre and Gembloux sites in Belgium as part of a $2.5 billion, three-year global restructuring meant to shift resources toward its late-stage pipeline and R&D. The move follows about 650 job cuts tied to closing a German manufacturing facility, and GSK says it will remain the largest biopharma employer in Belgium, a hub contributing over 50% of its global vaccine operations. GSK has not disclosed which specific roles will be affected.

  2. biospace.com47

    ‘Pharma bro’ Shkreli runs afoul of court’s lifetime pharma ban

    The FTC has asked a judge to hold Martin Shkreli in contempt for allegedly violating his lifetime pharma industry ban, in place since 2022, by trading pharma stocks and commenting on company management via livestreams on YouTube, X and Reddit. The complaint cites trades and commentary involving dozens of companies including Cassava Sciences, Capricor Therapeutics, Amgen and Eli Lilly. The FTC wants Shkreli to divest his shares, pay a fine equal to his profits and face escalating penalties for further violations.

  3. biocentury.com46

    Duracyte: Turning the patient into the bioreactor

    Duracyte, a Rice University spinout based in Houston, is developing subcutaneous implants of engineered human cells that continuously secrete biologics in the body for up to a year, with the aim of replacing repeated infusions and injections. The work has drawn roughly $120 million in non-dilutive funding. The company plans to start its first clinical trial in the first half of next year, testing an implant that produces the checkpoint inhibitor ipilimumab in patients with peritoneal cancer.

  4. biospace.com46

    European biotech leaders split on US-China fight for deal dominance, survey finds

    A BIO-Europe survey of 81 European biotech leaders, published Oct. 7, found no consensus on the top source of future innovation partnerships: 29 respondents picked the U.S., 24 picked China and 11 picked Europe. Europe received a "middling" score as a dealmaking hub, with capital availability named the biggest barrier to deals by 34 respondents and access to capital the top challenge to solve, cited by 42. Almost 80% blamed investor risk aversion for restricting investment.

  5. statnews.com40

    Helen Branswell, whose reporting on infectious diseases and public health drew acclaim, dies at 69

    Helen Branswell, STAT's infectious disease reporter since the outlet's founding in 2015 and previously a reporter at the Canadian Press, died Tuesday at age 69 from complications of cancer. She covered SARS, influenza, polio, Ebola and Covid-19, and was among the first to flag the unexplained pneumonias in China on Dec. 31, 2019. Her awards included the Victor Cohn Prize, the George Polk Award for Public Service, and a Pulitzer Prize finalist citation for early Covid coverage.

Oct 13Tue
  1. biopharmadive.com40

    Bausch + Lomb swaps CEOs; Merck reveals anticipated eye drug data

    Bausch + Lomb named board chair Thomas Appio interim CEO after he and Brent Saunders mutually agreed to Saunders' exit, and raised its 2026 earnings outlook. Merck disclosed that proliferative diabetic retinopathy adverse events occurred in 6.7% and 6.1% of remigromig patients versus 0.9% on Lucentis, with the drug not superior on secondary measures. Amgen and AstraZeneca reported nearly 70% of eosinophilic esophagitis patients on Tezspire's highest dose were in remission at 24 weeks; the FDA also approved Asahi Kasei's Hovilpri.

    Why it matters: CEO change at Bausch + Lomb plus pivotal safety and efficacy data on remigromig, Tezspire and a new HSV approval.

Oct 8Thu
  1. Cell84

    A non-canonical function of glutathione to suppress ferroptosis via FSP1.

    Glutathione suppresses ferroptosis independently of GPX4, protecting GPX4 knockout cells through a pathway pinpointed by genome-wide CRISPR-Cas9 screening: ferroptosis suppressor protein 1 (FSP1). FSP1 uses GSH to generate reduced ubiquinone, which scavenges oxidized lipids, and inhibition of FSP1 abolishes this protection in vitro and in vivo. The pathway differs from NAD(P)H-driven ubiquinone reduction by not requiring FAD.

    Why it matters: It uncovers a GPX4-independent route by which glutathione restrains ferroptosis, relevant to ferroptosis-related disease therapy.

  2. statnews.com43

    A mother-daughter quest to find fellow members of an ultra-rare genetic community

    A journalist and her nearly 17-year-old daughter Maya, who has Nicolaides-Baraitser syndrome, are tracing the condition and its global community of 337 known patients. The syndrome, first described in a 1993 paper by Paola Nicolaides and Michael Baraitser, has no cure, no medicines and no known disease progression. Their investigation has taken them to Cyprus, England and the United States to meet patients, families and the doctors involved.

  3. biospace.com40

    Q3 layoffs down YOY, with 90% fewer biopharma employees affected

    BioSpace tallies show biopharma layoffs fell sharply year over year in Q3, with a 56% drop in companies making or projecting cuts and a 90% plunge in affected employees; the 27 companies and 2,568 people affected are the lowest quarterly figures since tracking began in 2024. Eight Big Pharma companies accounted for cuts of 1,845 employees in the quarter, including Bristol Myers Squibb letting go of 265 people in Princeton, New Jersey, GSK closing a German vaccine site with about 650 job losses, and Novartis, whose 2026 disclosures total at least 922 people. Novo CEO Mike Maziar Doustdar said overall headcount has dropped by 13,000 over the past year, including 9,000 layoffs under a restructuring announced in September 2025 targeting around $1.25 billion in annualized savings.

  4. biopharmadive.com40

    Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial

    A Netherlands court blocked sales of Merck's subcutaneous Keytruda Qlex in eight European countries, siding with Halozyme in a patent dispute over its under-the-skin drug delivery technology. Separately, Enliven Therapeutics reached agreement with the FDA on a late-stage trial of relcobitinib in chronic myeloid leukemia, enrolling 450 people to test superiority at spurring a major molecular response. Halozyme is also challenging Merck in a U.S. court after a win in Germany.

    Why it matters: Patent ruling blocks subcutaneous Keytruda across Europe and FDA-aligned CML trial design sharpens competition for Novartis and Merck.

Oct 6Tue
  1. fda.gov45

    DesBio/Deseret Biologicals, Inc. - 735464 - 10/01/2026

    FDA's Center for Drug Evaluation and Research sent a warning letter dated October 1, 2026 (reference 735464) to DesBio/Deseret Biologicals CEO Jake Carter, citing the product "CHLA:10M," sold on desbio.com for relief of chlamydia-related symptoms, as an unapproved new drug under sections 301(d) and 505(a) of the FD&C Act. The letter follows a website review in July 2026 and notes that FDA has not approved any OTC drug product for treating or preventing any STI. The company must send a written response to FDAAdvisory@fda.hhs.gov within 15 business days or face possible seizure or injunction.

Oct 5Mon
  1. biospace.com40

    2 Massachusetts biotechs call it quits

    Boston-based Adecto Pharmaceuticals, which was developing an anti-ADAM8 monoclonal antibody for cancers unresponsive to conventional immunotherapy, ceased operations Sept. 30 after running out of financial runway, CEO Nora Minerva said on LinkedIn; she has filed a provisional patent on the lead antibody and is exploring ways to advance its development. Aviceda Therapeutics is also winding down after its nanoparticle AVD-104 missed the primary endpoint in a December-announced Phase 2b trial in geographic atrophy secondary to AMD, showing no statistical difference versus Astellas's Izervay, derailing two planned Phase 3 studies expected to start this year.

    Why it matters: Two Massachusetts biotechs are shutting down, one after a Phase 2b miss, illustrating the funding and clinical pressures on early-stage companies.

Oct 1Thu
  1. BioCentury43

    Beam lawsuit accuses YolTech and Serapha of tech theft

    Beam Therapeutics has sued YolTech and Serapha Bio, alleging trade secret theft. The suit, filed Sept. 25, claims former Beam scientist Zi Jun (Emma) Wang secretly co-founded YolTech while at Beam and used Beam technology in YolTech's lipid patent application and alpha-1 antitrypsin deficiency program, later licensed to Serapha, where Wang serves as CTO. YolTech CEO Yuxuan Wu categorically rejects the accusations.

Sep 30Wed
  1. statnews.com40

    STAT+: Merck discontinues a crucial antibiotic despite concerns over superbug resistance

    Merck has stopped supplying Recarbrio in the U.S., a three-drug combination antibiotic injection approved seven years ago for serious infections in adults and children, including hospital- or ventilator-associated pneumonia and complicated urinary tract and stomach infections in patients with limited or no treatment options. The company did not explain the decision and did not disclose Recarbrio sales in its regulatory filings. The FDA had designated the drug a treatment of last resort to mitigate antibiotic resistance, which limited its market potential.

    Why it matters: A large drugmaker withdrawing a last-resort antibiotic revives concern about industry commitment to antibiotics amid resistance.

Sep 11Fri
  1. Nature54

    The past and future impact of climate change on childhood malaria in Africa.

    Human-caused climate change has had a small net effect on childhood malaria across sub-Saharan Africa: rising temperatures probably increased cases in East and southern Africa but averted a comparable number in West Africa, a net impact of 1 excess case per 1,000 children (95% CI -4 to 6). Projections to 2100 suggest climate change could avert 1 to 20 cases per 1,000 children continent-wide, but limiting warming from 3 °C to under 2 °C could prevent an average of 5 excess cases per 1,000 in high-elevation East Africa and southern Africa.

    Why it matters: It settles a decades-old debate on whether climate change has already raised malaria burden in African children.

Sep 6Sun
  1. Cell61

    Structural basis for host membrane binding and remodeling by invading malaria parasites.

    The endogenous structure of the Plasmodium falciparum moving junction, purified from invasion-stalled parasites, reveals a sailboat-shaped 1:1:1:1 complex of PfAMA1, PfRON2, PfRON4 and PfRON5. Two PfRON2 transmembrane helices anchor the complex in the red blood cell membrane, while PfRON2/4/5 form a basic platform that wedges seven amphipathic helices into the bilayer, indicating active host-membrane remodeling. Guided by the structure, a rationally designed small protein binder inhibits invasion.

    Why it matters: First native structure of the malaria moving junction enables structure-based design of an invasion inhibitor.

Aug 24Mon
  1. fiercepharma.com42

    Cellares CEO seeks to 'resize' company after loss of 'large' cell therapy manufacturing customer

    Cellares co-founder and CEO Fabian Gerlinghaus said a "large pharmaceutical customer" has ended its partnership with the automated cell therapy manufacturer, requiring the South San Francisco company, which emerged in 2019, to "resize" through job cuts of unspecified scope. The unidentified customer's departure was "specific" to that company, and Cellares says the reduction will concentrate resources on clinical and commercial programs. Gerlinghaus says the customer base has more than doubled since the start of the year, following deals with Bristol Myers Squibb, Kite Pharma, Sonoma Biotherapeutics and a 10-year supply pact with Cabaletta Bio for rese-cel.

  2. fiercepharma.com47

    Daiichi Sankyo promotes Ken Keller to lead new commercialization unit

    Daiichi Sankyo has promoted Ken Keller, who has led its global oncology business for five years, to chief commercialization officer of a new globally integrated commercialization unit starting April 1. The restructured organization covers five regions, with internal appointments including Yuichi Yomasu in China, Markus Kosch in Europe, Marcelo Goncalves in Latin America, Kenji Shigeta in North America and Nobuo Murakami in Japan, Asia and the Pacific. The unit supports Daiichi Sankyo's plan to become a top-five oncology company by 2035 and to make five drugs available in 20 new indications by 2030.

Aug 21Fri
  1. fiercepharma.com48

    Roche earmarks $750M to double the size of its Oregon manufacturing facility

    Roche will invest $750 million to double the size of its Genentech unit's manufacturing campus in Hillsboro, Oregon, adding a fill-finish plant for drug-delivery devices such as prefilled syringes and auto-injectors. The 75-acre site has produced oncology, immunology and neurology treatments for 20 years. Roche plans to have the new plant operational in 2031 and to add 250 manufacturing jobs, part of a $50 billion U.S. investment pledge announced last April.

Aug 20Thu
  1. statnews.com40

    Trust in science: A new STAT initiative

    STAT has created a trust-in-science reporter and editor role and hired Nicholas Florko, who spent six years at STAT before two years at The Atlantic, to cover misinformation about science. The initiative is funded by the Dana, Greenwall, John Templeton, and Boston foundations, and Florko will appear at the STAT Summit in Boston on Oct. 14-15. Additional stories and First Opinion essays on trust in science are planned.

  2. statnews.com49

    STAT+: American Cancer Society cancels alcohol industry fundraiser

    The American Cancer Society has canceled its Wine and Spirits Industry Gala, which was scheduled for October at Manhattan's Rainbow Room. Spokesperson Michele Money-Carson said the decision is part of ACS's review of how its fundraising aligns with its mission and prevention guidance. STAT reported this summer that the gala had raised at least $22 million from alcohol industry executives, drawing criticism given alcohol's links to cancer.

Aug 19Wed
  1. statnews.com47

    STAT+: Nonprofit health system raked in $1.1 billion this year from stake in medical billing firm

    Bon Secours Mercy Health, a Cincinnati-based nonprofit health system, collected $1.1 billion this year from its minority stake in medical billing firm Ensemble Health Partners, exceeding its operating income so far this year. The total includes a $671 million payment received when Ensemble signed a new private equity sponsor about two weeks ago, plus a $427 million distribution recorded in February. Both appeared in the system's second-quarter financial report, which ended June 30.

Aug 14Fri
  1. Cell76

    Coordinated RNA- and protein-templated synthesis of double-stranded DNA by a dual reverse transcriptase immune system.

    DRT3 antiviral immunity depends on cooperation between class 1 and class 2 reverse transcriptase activities that together produce self-complementary double-stranded DNA. DRT3a copies a 5'-ACACAC-3' RNA template to make poly-(dTdG) repeats, while DRT3b makes poly-(dCdA) repeats without any nucleic acid template, using active-site-adjacent residues as nucleotide gates, as shown by cryo-electron microscopy. DRT3 is toxic in cells lacking RecBCD, and the phage-encoded RecBCD inhibitor Gam triggers abortive infection, defining how complementary DNA synthesis drives defense.

    Why it matters: It explains how two reverse transcriptases with distinct templating strategies cooperate to build antiviral double-stranded DNA.

  2. STAT News41

    STAT+: Drug-testing lab that has sparked controversy sues group that develops drug standards over criticism

    Valisure, a drug-testing laboratory that previously clashed with regulators over impurities found in widely used medicines, has sued U.S. Pharmacopeia in a U.S. court. Valisure argues USP falsely claimed in a 2023 white paper that it used unvalidated methods for quality testing that can produce misleading results and unnecessary concern, and did so to promote trust in a system that financially benefits USP. The case now proceeds in court.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org